UNSPSC 51351633: Estrone sodium sulfate

This classification denotes an estrogen C18H21O5S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6K6FDA543A, chemically known as estra-1,3,5(10)-trien-17-one, 3-(sulfooxy)-, sodium salt, but more generally known as estrone sodium sulfate, which bears US NIH Compound Identifier 23667301. European Medicines Agency schedules Estrone sodium sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01976MIG.

Most nations, for tariff and trade purposes, schedule estrone sodium sulfate under HS 29372300 and SITC 54153. As of Q4 2014, ESTRONE SODIUM SULFATE remains US FDA's Preferred Term for this commodity. Estrone sodium sulfate bears US NLM identifiers UMLS ID C0304783 and NCI Concept Code C61942. SMILES: C[C@]12CC[C@@H]3C4CCC(CC4CC[C@H]3[C@@H]1CCC2=O)OS(=O)(=O)[O-].[NA+].

UNSPSC 51351633 Estrone sodium sulfate is a Commodity code covering pharmaceutical manufacturing and supply through state and local cooperative purchasing agreements. State and local governments procure estrone sodium sulfate and related pharmaceutical products as part of broader multi-source generic drug frameworks that distribute medications across public health facilities, correctional institutions, and other state or local care settings. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the primary issuing body visible in recent activity, managing procurement on behalf of multiple participating states and local entities. Vendors responding to pharmaceutical commodity codes like this one must hold current Good Manufacturing Practices (cGMP) certification and Drug Supply Chain Security Act (DSCSA) compliance, maintain contractual relationships with authorized wholesale distributors including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, carry comprehensive insurance including $5,000,000 in commercial general liability coverage and $2,000,000 each in network security and professional liability, and supply products with FDA approval and minimum six-month shelf life guarantees.

MMCAP's January 2026 RFP for generic multi-source pharmaceuticals and OTC products (Solicitation S1070000015802, response due March 26, 2026) represents the primary recent opportunity under this code, with participating states including Minnesota and Oregon. The solicitation emphasizes price competitiveness as the dominant evaluation factor (75 percent of scoring), followed by fixed pricing for the contract term (10 percent), compliance with administrative and EDI requirements (5 percent each), and willingness to accept a 3 percent administrative fee (5 percent). Awarded vendors will supply products through designated wholesalers with effective dates of July 1, 2026, under two-year initial contracts for new responders or amendments aligning with existing agreement terms through June 30, 2028 at MMCAP's discretion. Proposals require detailed product information including National Drug Codes, SKUs, UPCs, strength, dosage form, and manufacturing location, submitted through the ePro procurement system in CSV format, with a question cutoff of February 18, 2026.